Phase I Study of ICP-332 in Healthy Subjects

InnoCare Pharma

Status and phase: Enrolling; Phase 1

Conditions: Healthy Subjects

Treatments: Drug: ICP-332 Tablets; Drug: ICP-332 Placebo Tablets

Study type: Interventional

Funder types: Industry

Identifiers

NCT06530966

ICP-CL-00605

Details and patient eligibility

About

A multiple ascending dose phase I study of ICP-332 in healthy subjects

Enrollment: 24 estimated patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. Voluntarily sign the informed consent form
2. Body mass index (BMI) of ≥ 18.5 kg/m2 and < 30 kg/m2
3. Male or infertile female subjects who are between 18-55 years old (inclusive)

Exclusion criteria

1. Significant current or past acute or chronic disease or condition.
2. A history of tuberculosis or current active/latent infection.
3. With a history of drug or food allergy, or allergy to any of the composition components of the study drug, or allergic disease.
4. Subjects with clinically significant abnormalities in the screening examinations.

Trial design

Primary purpose: Other

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

24 participants in 2 patient groups, including a placebo group

ICP-332

Experimental group

Treatment:

Drug: ICP-332 Tablets

Placebo

Placebo Comparator group

Treatment:

Drug: ICP-332 Placebo Tablets